Cargando…

Long-Term Effect of Alogliptin on Glycemic Control in Japanese Patients With Type 2 Diabetes: A 3.5-Year Observational Study

BACKGROUND: The goal of the current study was to investigate the long-term effects (after 3 years or more) of alogliptin on glycemic control in Japanese patients with type 2 diabetes. METHODS: We retrospectively studied the effect of alogliptin on glycemic control in the patients with type 2 diabete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takebayashi, Kohzo, Suzuki, Tatsuhiko, Naruse, Rika, Hara, Kenji, Suetsugu, Mariko, Tsuchiya, Takafumi, Inukai, Toshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544487/ https://www.ncbi.nlm.nih.gov/pubmed/28811859 http://dx.doi.org/10.14740/jocmr3118w

Ejemplares similares

Circulating SerpinB1 levels and clinical features in patients with type 2 diabetes
por: Takebayashi, Kohzo, et al.
Publicado: (2016)

Serum Betatrophin Levels and Clinical Features in Patients With Poorly Controlled Type 2 Diabetes
por: Takebayashi, Kohzo, et al.
Publicado: (2017)

Association between angiopoietin-like protein 2 and lectin-like oxidized low-density lipoprotein receptor 1 ligand containing apolipoprotein B in patients with type 2 diabetes
por: Suzuki, Tatsuhiko, et al.
Publicado: (2018)

Hb Phnom Penh Showing Falsely High or Reasonable HbA1c Values Depending on the Type of High-performance Liquid Chromatography System
por: Hara, Kenji, et al.
Publicado: (2019)

Isolated Adrenocorticotropic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma
por: Takebayashi, Kohzo, et al.
Publicado: (2018)

Association of circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 with inflammatory markers and urinary albumin excretion in patients with type 2 diabetes
por: Takebayashi, Kohzo, et al.
Publicado: (2021)

Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus
por: Takebayashi, Kohzo, et al.
Publicado: (2017)

Seasonal variations and the influence of COVID-19 pandemic on hemoglobin A1c, glycoalbumin, and low-density lipoprotein cholesterol
por: Takebayashi, Kohzo, et al.
Publicado: (2022)

Severe Non-Islet Cell Hypoglycemia From Ileum-Origin Gastrointestinal Stromal Tumor Producing Insulin-Like Growth Factor-2 in a Patient With Liver Cirrhosis Due to Chronic Hepatitis B
por: Takebayashi, Kohzo, et al.
Publicado: (2020)

Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index
por: Aoki, Chie, et al.
Publicado: (2017)

Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1
por: Tonouchi, Ryosuke, et al.
Publicado: (2017)

A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes
por: Nishimura, Rimei, et al.
Publicado: (2019)

Investigation of Alogliptin-Loaded In Situ Gel Implants by 2(3) Factorial Design with Glycemic Assessment in Rats
por: Ibrahim, Tarek M., et al.
Publicado: (2022)

Effects of androgens and estrogens on sirtuin 1 gene expression in human aortic endothelial cells
por: Tsuchiya, Takafumi, et al.
Publicado: (2020)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Liquid Chromatographic Determination of Alogliptin in Bulk and in its Pharmaceutical Preparation
por: El-Bagary, Ramzia I., et al.
Publicado: (2012)

Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin
por: Yin, Hao, et al.
Publicado: (2013)

Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis
por: Shima, Hisato, et al.
Publicado: (2019)

Necrotizing Pancreatitis Secondary to Hydrochlorothiazide and Alogliptin: A Case Report
por: Del Rio, Teresa, et al.
Publicado: (2023)

Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study
por: Mita, Tomoya, et al.
Publicado: (2023)

Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels
por: Ohashi, Naro, et al.
Publicado: (2014)

Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
por: Ueki, Kohjiro, et al.
Publicado: (2021)

Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
por: Mita, Tomoya, et al.
Publicado: (2017)

Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects
por: Kapoor, Shailendra
Publicado: (2012)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Alogliptin improves survival and health of mice on a high‐fat diet
por: Zhu, Biao, et al.
Publicado: (2019)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

Immunohistochemical Pharmacokinetics of the Anti-diabetes Drug Alogliptin in Rat Kidney and Liver
por: Yamamoto, Yutaro, et al.
Publicado: (2020)

Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro
por: Shigematsu, Nao, et al.
Publicado: (2020)

Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
por: Kaku, Kohei, et al.
Publicado: (2019)

Formulation and Optimization of Alogliptin-Loaded Polymeric Nanoparticles: In Vitro to In Vivo Assessment
por: Mohanty, Dibyalochan, et al.
Publicado: (2022)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
por: Kim, Hae Jin, et al.
Publicado: (2022)

Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

Treatment of Streptozotocin-Induced Diabetic Rats with Alogliptin: Effect on Vascular and Neural Complications
por: Davidson, Eric P., et al.
Publicado: (2011)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis
por: Cai, Yuli, et al.
Publicado: (2017)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ti8gq9koru5qkeetqqg91oehdp